For research use only. Not for therapeutic Use.
Bederocin (Cat.No:I003799), also known as REP-8839, is a novel methionyl-tRNA synthetase (MetS) inhibitor with potent antibacterial activity against clinical isolates of Staphylococcus aureus, Streptococcus pyogenes, and other clinically important gram-positive bacteria but little activity against gram-negative bacteria. REP8839 was highly bound to the protein of human serum, and activity was not greatly influenced by inoculum size but was affected by pH, exhibiting optimal antibacterial activity in a neutral medium rather than a weak acidic medium.
| Catalog Number | I003799 |
| CAS Number | 757942-43-1 |
| Synonyms | REP8839; REP-8839; REP 8839; Bederocin;2-((3-(((4-bromo-5-(1-fluorovinyl)-3-methylthiophen-2-yl)methyl)amino)propyl)amino)quinolin-4(1H)-one |
| Molecular Formula | C20H21BrFN3OS |
| Purity | ≥95% |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term or -20 °C for long term |
| IUPAC Name | 2-[3-[[4-bromo-5-(1-fluoroethenyl)-3-methylthiophen-2-yl]methylamino]propylamino]-1H-quinolin-4-one |
| InChI | InChI=1S/C20H21BrFN3OS/c1-12-17(27-20(13(2)22)19(12)21)11-23-8-5-9-24-18-10-16(26)14-6-3-4-7-15(14)25-18/h3-4,6-7,10,23H,2,5,8-9,11H2,1H3,(H2,24,25,26) |
| InChIKey | BGJMKHPWCFXMOW-UHFFFAOYSA-N |
| SMILES | CC1=C(SC(=C1Br)C(=C)F)CNCCCNC2=CC(=O)C3=CC=CC=C3N2 |
| Reference | </br>1: Hussain T, Yogavel M, Sharma A. Inhibition of protein synthesis and malaria parasite development by drug targeting of methionyl-tRNA synthetases. Antimicrob Agents Chemother. 2015 Apr;59(4):1856-67. doi: 10.1128/AAC.02220-13. Epub 2015 Jan 12. PubMed PMID: 25583729; PubMed Central PMCID: PMC4356764.</br>2: Faqi AS, Bell SJ, Gill S, Colagiovanni DB. An intranasal irritation assessment of antibacterial ointment alone or in combination with mupirocin versus Bactroban Nasal in rabbits. Regul Toxicol Pharmacol. 2009 Oct;55(1):28-32. doi: 10.1016/j.yrtph.2009.05.017. Epub 2009 Jun 2. PubMed PMID: 19497343.</br>3: Green LS, Bullard JM, Ribble W, Dean F, Ayers DF, Ochsner UA, Janjic N, Jarvis TC. Inhibition of methionyl-tRNA synthetase by REP8839 and effects of resistance mutations on enzyme activity. Antimicrob Agents Chemother. 2009 Jan;53(1):86-94. doi: 10.1128/AAC.00275-08. Epub 2008 Nov 17. PubMed PMID: 19015366; PubMed Central PMCID: PMC2612134.</br>4: Critchley IA, Ochsner UA. Recent advances in the preclinical evaluation of the topical antibacterial agent REP8839. Curr Opin Chem Biol. 2008 Aug;12(4):409-17. doi: 10.1016/j.cbpa.2008.06.011. Epub 2008 Jul 11. Review. PubMed PMID: 18620074.</br>5: Ochsner UA, Young CL, Stone KC, Dean FB, Janjic N, Critchley IA. Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase. Antimicrob Agents Chemother. 2005 Oct;49(10):4253-62. PubMed PMID: 16189106; PubMed Central PMCID: PMC1251548.</br>6: Critchley IA, Young CL, Stone KC, Ochsner UA, Guiles J, Tarasow T, Janjic N. Antibacterial activity of REP8839, a new antibiotic for topical use. Antimicrob Agents Chemother. 2005 Oct;49(10):4247-52. PubMed PMID: 16189105; PubMed Central PMCID: PMC1251549.</br></br></br> |
